
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1785255/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nonresponse in a community cohort study. Journal of Clinical Epidemiology, 2002, 55, 775-781.	5.0	106
2	Neutrophil Gelatinase-Associated Lipocalin. Chest, 2010, 138, 888-895.	0.8	89
3	Comparison of 2011 and 2007 Global Initiative for Chronic Obstructive Lung Disease Guidelines for Predicting Mortality and Hospitalization. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 51-59.	5.6	78
4	Respiratory symptoms, COPD severity, and health related quality of life in a general population sample. Respiratory Medicine, 2008, 102, 399-406.	2.9	68
5	Respiratory symptoms in adults are related to impaired quality of life, regardless of asthma and COPD: results from the European community respiratory health survey. Health and Quality of Life Outcomes, 2010, 8, 107.	2.4	66
6	The effect of educational level on the incidence of asthma and respiratory symptoms. Respiratory Medicine, 2004, 98, 730-736.	2.9	63
7	Predictors of Exacerbations in Chronic Obstructive Pulmonary Disease - Results from the Bergen COPD Cohort Study. PLoS ONE, 2014, 9, e109721.	2.5	62
8	Predictors of diagnostic yield in bronchoscopy: a retrospective cohort study comparing different combinations of sampling techniques. BMC Pulmonary Medicine, 2008, 8, 2.	2.0	61
9	Antimicrobial peptide levels are linked to airway inflammation, bacterial colonisation and exacerbations in chronic obstructive pulmonary disease. European Respiratory Journal, 2017, 49, 1601328.	6.7	53
10	The respiratory virome and exacerbations in patients with chronic obstructive pulmonary disease. PLoS ONE, 2019, 14, e0223952.	2.5	51
11	Oxygen desaturation in 6-min walk test is a risk factor for adverse outcomes in COPD. European Respiratory Journal, 2016, 48, 82-91.	6.7	48
12	Association of exposure to environmental tobacco smoke in childhood with chronic obstructive pulmonary disease and respiratory symptoms in adults. Respirology, 2012, 17, 499-505.	2.3	46
13	Changes in Respiratory Symptoms and Health-Related Quality of Life. Chest, 2007, 131, 1890-1897.	0.8	39
14	Growth differentiation factor-15 is a predictor of important disease outcomes in patients with COPD. European Respiratory Journal, 2017, 49, 1601298.	6.7	38
15	TNF-α is associated with loss of lean body mass only in already cachectic COPD patients. Respiratory Research, 2012, 13, 48.	3.6	37
16	Protected sampling is preferable in bronchoscopic studies of the airway microbiome. ERJ Open Research, 2017, 3, 00019-2017.	2.6	34
17	The prevalence of undiagnosed renal failure in a cohort of COPD patients in western Norway. Respiratory Medicine, 2012, 106, 361-366.	2.9	33
18	Body composition and plasma levels of inflammatory biomarkers in COPD. European Respiratory Journal, 2010, 36, 1027-1033.	6.7	31

#	Article	IF	CITATIONS
19	High prevalence of respiratory symptoms during air travel in patients with COPD. Respiratory Medicine, 2011, 105, 50-56.	2.9	31
20	Variability of within-breath reactance in COPD patients and its association with dyspnoea. European Respiratory Journal, 2015, 45, 625-634.	6.7	31
21	Laboratory contamination in airway microbiome studies. BMC Microbiology, 2019, 19, 187.	3.3	31
22	Socioeconomic risk factors for lung function decline in a general population. European Respiratory Journal, 2010, 36, 480-487.	6.7	30
23	Comparison of inflammatory markers in induced and spontaneous sputum in a cohort of COPD patients. Respiratory Research, 2014, 15, 138.	3.6	28
24	Coagulation markers as predictors for clinical events in <scp>COPD</scp> . Respirology, 2021, 26, 342-351.	2.3	28
25	Insomnia symptoms, objectively measured sleep, and disease severity in chronic obstructive pulmonary disease outpatients. Sleep Medicine, 2013, 14, 1328-1333.	1.6	27
26	Dynamic differences in dietary polyunsaturated fatty acid metabolism in sputum of COPD patients and controls. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 224-233.	2.4	26
27	Comparing microbiota profiles in induced and spontaneous sputum samples in COPD patients. Respiratory Research, 2017, 18, 164.	3.6	24
28	Risk factors for lung cancer in COPD – results from the Bergen COPD cohort study. Respiratory Medicine, 2019, 152, 81-88.	2.9	24
29	Occupational exposure and incidence of respiratory disorders in a general population. Scandinavian Journal of Work, Environment and Health, 2009, 35, 454-461.	3.4	24
30	Different COPD Disease Characteristics are Related to Different Outcomes in the 6-minute Walk Test. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2012, 9, 227-234.	1.6	23
31	Exposure to environmental tobacco smoke in a general population. Respiratory Medicine, 2007, 101, 277-285.	2.9	22
32	The Bergen COPD microbiome study (MicroCOPD): rationale, design, and initial experiences. European Clinical Respiratory Journal, 2014, 1, 26196.	1.5	21
33	Sputum microbiota and inflammation at stable state and during exacerbations in a cohort of chronic obstructive pulmonary disease (COPD) patients. PLoS ONE, 2019, 14, e0222449.	2.5	21
34	Physical activity and longitudinal change in 6-minÂwalk distance in COPD patients. Respiratory Medicine, 2014, 108, 86-94.	2.9	20
35	Macrophage migration inhibitory factor, a role in COPD. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L1-L7.	2.9	19
36	Productivity losses in chronic obstructive pulmonary disease: a population-based survey. BMJ Open Respiratory Research, 2014, 1, e000049.	3.0	18

#	Article	IF	CITATIONS
37	The association of tidal EFL with exercise performance, exacerbations, and death in COPD. International Journal of COPD, 2017, Volume 12, 2179-2188.	2.3	18
38	Systemic mannose-binding lectin is not associated with chronic obstructive pulmonary disease. Respiratory Medicine, 2010, 104, 283-290.	2.9	17
39	The pulmonary mycobiome—A study of subjects with and without chronic obstructive pulmonary disease. PLoS ONE, 2021, 16, e0248967.	2.5	16
40	The airway microbiota and exacerbations of COPD. ERJ Open Research, 2020, 6, 00168-2020.	2.6	13
41	ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF. BMJ Open Respiratory Research, 2020, 7, e000598.	3.0	11
42	Exploring protocol bias in airway microbiome studies: one versus two PCR steps and 16S rRNA gene region V3 V4 versus V4. BMC Genomics, 2021, 22, 3.	2.8	11
43	Predictors for P _a O ₂ and Hypoxemic Respiratory Failure in COPD–A Three-Year Follow-up. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 531-538.	1.6	10
44	Inflammatory cytokine response to exercise in alpha-1-antitrypsin deficient COPD patients â€~on' or â€~off' augmentation therapy. BMC Pulmonary Medicine, 2014, 14, 106.	тм 2.0	10
45	Incidence of utilization- and symptom-defined COPD exacerbations in hospital- and population-recruited patients. International Journal of COPD, 2016, Volume 11, 2099-2108.	2.3	10
46	Diffusion capacity and CT measures of emphysema and airway wall thickness – relation to arterial oxygen tension in COPD patients. European Clinical Respiratory Journal, 2016, 3, 29141.	1.5	10
47	Lung hyperinflation and functional exercise capacity in patients with COPD – a three-year longitudinal study. BMC Pulmonary Medicine, 2018, 18, 187.	2.0	10
48	Guideline adherence in hospital recruited and population based COPD patients. BMC Pulmonary Medicine, 2018, 18, 195.	2.0	9
49	Complications and discomfort after research bronchoscopy in the MicroCOPD study. BMJ Open Respiratory Research, 2020, 7, e000449.	3.0	9
50	Associations between obstructive lung disease and symptoms of obstructive sleep apnoea in a general population. Clinical Respiratory Journal, 2018, 12, 31-39.	1.6	8
51	Characteristics of 24-hourÂambulatory blood pressure monitoring in a COVID-19 survivor. Future Cardiology, 2021, 17, 1321-1326.	1.2	8
52	One Year Change in 6-Minute Walk Test Outcomes is Associated with COPD Prognosis. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2020, 17, 662-671.	1.6	7
53	Paraneoplastic <scp>H</scp> u and <scp>CRMP5</scp> antibodies are present in smokers without cancer or neurological disease. Respirology, 2014, 19, 730-734.	2.3	6
54	Median regression spline modeling of longitudinal FEV1 measurements in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) patients. PLoS ONE, 2017, 12, e0190061.	2.5	6

#	Article	IF	CITATIONS
55	Non-Response in Telephone Surveys of Copd Patients Does Not Introduce Bias. Journal of Telemedicine and Telecare, 2013, 19, 40-44.	2.7	5
56	Change in pulmonary diffusion capacity in a general population sample over 9 years. European Clinical Respiratory Journal, 2016, 3, 31265.	1.5	5
57	Expert opinion of mediastinal lymph node positions from an intrabronchial view. BMC Pulmonary Medicine, 2016, 16, 15.	2.0	5
58	A pilot study of hot-wire, ultrasonic and wedge-bellows spirometer inter- and intra-variability. BMC Research Notes, 2017, 10, 497.	1.4	4
59	Motivation and response rates in bronchoscopy studies. Multidisciplinary Respiratory Medicine, 2019, 14, 14.	1.5	4
60	The lower airways microbiome and antimicrobial peptides in idiopathic pulmonary fibrosis differ from chronic obstructive pulmonary disease. PLoS ONE, 2022, 17, e0262082.	2.5	4
61	Performance of Five Metagenomic Classifiers for Virus Pathogen Detection Using Respiratory Samples from a Clinical Cohort. Pathogens, 2022, 11, 340.	2.8	4
62	Clinical information predicting severe obstructive sleep apnea: A cross-sectional study of patients waiting for sleep diagnostics. Respiratory Medicine, 2022, 197, 106860.	2.9	4
63	Factors associated with coronary heart disease in COPD patients and controls. PLoS ONE, 2022, 17, e0265682.	2.5	1
64	Response to Leiro et al Respiratory Medicine, 2010, 104, 1387.	2.9	0